美股异动 | 治疗遗传性骨病在研药物临床试验失败 Ultragenyx Pharmaceutical(RARE.US)盘前暴跌超42%

Core Viewpoint - Ultragenyx Pharmaceutical's stock plummeted over 42% in pre-market trading following the announcement that its investigational drug for a specific genetic bone disease failed to meet primary efficacy endpoints in late-stage clinical trials [1] Company Summary - The stock price of Ultragenyx Pharmaceutical (RARE.US) fell to $19.69 as of the latest report [1] - The failure of the drug in clinical trials represents a significant setback for the company, impacting investor confidence and market valuation [1]